Adam Walsh

Award winning biotechnology equity research professional with 20+ years of financial experience at leading investment banks. Founding Managing Director of Jefferies Biotechnology Equity Research Franchise​

Prior to joining Catalytic Life Sciences (CLS), Adam spent 5 years as Managing Director and Senior Biotechnology Analyst at Stifel covering a broad range of therapeutics companies. While there in 2018, Adam was ranked #1 Top Stock Picker and #2 Top Earnings Estimator for Biotechnology Equity Research Analysts by Thompson Reuters / StarMine. Prior to Stifel, Adam held a similar position at Canaccord.

Early in his sell-side career (2002), Adam was recruited to Jefferies to be the company’s first Biotechnology Equity Research Analyst. As Founding Managing Director​, Adam spent eight years helping to lay the initial groundwork for today’s successful platform.

Adam holds M.D. and M.B.A. degrees from Tufts University and B.S. (Business Administration) and B.A. (Psychology) degrees from the University of Colorado at Boulder.  Adam holds Series 7, 63, 79, 86, 87 securities licenses.